Dezecapavir vs Islatravir/lenacapavir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV capsid · full HIV pipeline

Dezecapavir

Developed by ViiV Healthcare

Phase 2 in HIVsmall molecule
Partial signal

NCT06039579 · Phase 2 · completed

This Phase 2 trial was randomized, double-blind (participant and investigator), and placebo-controlled, with 44 participants allocated across multiple dose groups of VH4004280 and VH4011499. The primary endpoint was the maximum change in plasma HIV-1 RNA during 10-day monotherapy; posted results for VH4011499 show mean declines of about -1.8 to -2.2 log10 in active arms versus -0.18 log10 in placebo, but no p-values or confidence intervals are reported. Because the groups are very small (6-7 active vs 3 placebo) and the statistical significance of the primary comparison is not documented, this constitutes real but limited evidence.

Next expected readout: February 2027 · NCT07934719 (registry estimate)

Reported efficacy

Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969) (unclear)

Result source: NCT06039579

Islatravir/lenacapavir

Developed by Gilead Sciences and partners

Phase 3 in HIVsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDezecapavirIslatravir/​lenacapavir
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Trial running · NCT06630286
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Trial running · NCT06630286
CD4 count, change (week 48)—Not reported—Trial running · NCT06630286

HIV-1 RNA below 50 copies/mL (week 48)

Dezecapavir
—Not reported
Islatravir/​lenacapavir
—Trial running · NCT06630286

HIV-1 RNA 50 copies/mL or more (week 48)

Dezecapavir
—Not reported
Islatravir/​lenacapavir
—Trial running · NCT06630286

CD4 count, change (week 48)

Dezecapavir
—Not reported
Islatravir/​lenacapavir
—Trial running · NCT06630286
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Islatravir/lenacapavir: no structured comparison results are available for HIV.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dezecapavir: 3 of 4 rows · Islatravir/lenacapavir: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDezecapavir
Dropout rate
0%Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 17 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%1875 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%625 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%400 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%300 mg + Midazolam (MDZ) PiB
NCT05393271 · Phase 1 · combination
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg Tablet
NCT05393271 · Phase 1 · monotherapy
0%125 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%25 mg PiB
NCT05393271 · Phase 1 · monotherapy
Discontinued due to AEs
—Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 17 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—1875 mg PiB
NCT05393271 · Phase 1 · monotherapy
—625 mg PiB
NCT05393271 · Phase 1 · monotherapy
—400 mg PiB
NCT05393271 · Phase 1 · monotherapy
—300 mg + Midazolam (MDZ) PiB
NCT05393271 · Phase 1 · combination
—200 mg PiB
NCT05393271 · Phase 1 · monotherapy
—200 mg PiB
NCT05393271 · Phase 1 · monotherapy
—200 mg Tablet
NCT05393271 · Phase 1 · monotherapy
—125 mg PiB
NCT05393271 · Phase 1 · monotherapy
—25 mg PiB
NCT05393271 · Phase 1 · monotherapy
Serious AEs
—Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 17 more results
0%Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%1875 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%625 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%400 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%300 mg + Midazolam (MDZ) PiB
NCT05393271 · Phase 1 · combination
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg Tablet
NCT05393271 · Phase 1 · monotherapy
0%125 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%25 mg PiB
NCT05393271 · Phase 1 · monotherapy
Most frequent reported AEs
Dose Level 1a
influenza 14.3% (placebo 33.3%)
proteinuria 14.3% (placebo 0%)
rash 14.3% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 14 more results
Dose Level 1
headache 14.3% (placebo 0%)
upper respiratory tract infection 14.3% (placebo 0%)
alanine aminotransferase increased 0% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
Dose Level 2
arthralgia 16.7% (placebo 0%)
dermatophytosis 16.7% (placebo 0%)
ear pain 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Dose Level 2
asthenia 16.7% (placebo 0%)
dermatitis acneiform 16.7% (placebo 0%)
diarrhoea 16.7% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
Pre-specified Dose
nausea 28.6% (placebo 0%)
alanine aminotransferase increased 14.3% (placebo 0%)
aspartate aminotransferase increased 14.3% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Pre-specified Dose
vessel puncture site haematoma 28.6% (placebo 0%)
headache 14.3% (placebo 0%)
hypokalaemia 14.3% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
1875 mg PiB
total bile acids increased 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
625 mg PiB
gastroenteritis 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
400 mg PiB
dry skin 16.7% (placebo 0%)
skin abrasion 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
300 mg + Midazolam (MDZ) PiB
somnolence 25% (placebo 0%)
dizziness 12.5% (placebo 0%)
feeling abnormal 12.5% (placebo 0%)
NCT05393271 · Phase 1 · combination
200 mg PiB
activated partial thromboplastin time prolonged 33.3% (placebo 0%)
blood triglycerides increased 16.7% (placebo 0%)
lipase increased 16.7% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
200 mg PiB
diarrhoea 33.3% (placebo 0%)
headache 33.3% (placebo 0%)
nausea 33.3% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
200 mg Tablet
medical device site dermatitis 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
125 mg PiB
medical device site dermatitis 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
25 mg PiB
blood creatine phosphokinase increased 16.7% (placebo 20%)
haematocrit decreased 16.7% (placebo 0%)
haemoglobin decreased 16.7% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 9 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dezecapavir

HIV-1 RNA -1.834 vs -0.176 placebo logDose Level 1
absolute change · log
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.797 vs -0.176 placebo logDose Level 2
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
-2.165 vs -0.176 placebo logPre-specified Dose
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
HIV-1 RNA -1.801 log @ 1.57wkDose Level 1
absolute change · log
No placebo or comparator arm
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.75 log @ 1.57wkDose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
-2.165 log @ 1.57wkPre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dezecapavir's landscape · Islatravir/lenacapavir's landscape